BioGenerator is seeking qualified candidates to join our team and help us achieve our mission of promoting economic growth and regional prosperity. BioGenerator, the non-profit investment arm of BioSTL, was […]
Read MoreIndalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965 October 21, 2019 Key milestone reached in adaptive Phase 1/1b clinical trial that began in April 2019 […]
Read MoreBioGenerator portfolio company noted for its ‘promising technology’ to more quickly and affordably bring vaccines to market ST. LOUIS – St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines […]
Read MoreST. LOUIS, Aug. 6, 2019 – Bayer has awarded BioSTL, a St. Louis-based non-profit which advances and promotes the region’s growing bioscience, innovation and technology community, a $1.5 million grant […]
Read MoreMediBeacon Enters into $30 Million Investment and Exclusive Commercialization Partnership in Greater China with Huadong Medicine MediBeacon and Huadong Medicine will collaboratively work to reach regulatory approval on MediBeacon’s entire […]
Read MoreGrant expands BioGenerator Labs and Commercialization Resources ST. LOUIS – BioGenerator, the investment arm of BioSTL, has won a $750,000 grant from the U.S. Department of Commerce Economic Development Administration […]
Read MoreReadout adds veteran executive leadership to its management team ST. LOUIS – Readout, an early-stage digital health company, announced completion of its initial funding round, led by BioGenerator, the investment […]
Read MoreAdarza BioSystems to reveal ZIVA platform at AAI 2019: a fully automated protein multiplex detection system ST. LOUIS (May 2, 2019) — Biotech startup Adarza Biosystems, Inc. announced today that […]
Read MorePress release: https://canopybiosciences.com/news/canopy-biosciences-acquires-zellkraftwerk-gmbh/ Acquisition gives St. Louis-based Canopy an international reach Article by David Nicklaus Expanding internationally, being backed by a prominent private equity firm and tripling in size […]
Read MoreIndalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965 – Oral integrin antagonist inhibits multiple processes of pathologic fibrosis – Indalo to present at […]
Read More